Navigation Links
BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
Date:10/25/2007

SAN FRANCISCO, Oct. 25 /PRNewswire/ -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing novel cancer therapies, today announced molecular biomarker data demonstrating the overexpression of the PARP (poly-ADP-ribose polymerase) protein in multiple cancers, including ovarian, breast and lung tumors. The research is the first demonstration of PARP overexpression in specific types of cancer. This insight is being used to guide the clinical development of the company's pipeline of PARP inhibitor candidates.

The results were presented at the American Association for Cancer Research-National Cancer Institute-European Organization for Research and Treatment of Cancer (AACR-NCI-EORTC) International Conference on Molecular Targets and Cancer Therapeutics in San Francisco.

"These results allow us to focus our clinical development plan for BSI-201 by targeting tumors types that have the greatest probability of clinical success," said BiPar Executive Vice President Barry Sherman, M.D.

BiPar researchers used the Gene Logic Inc. BioExpress(R) System database to analyze PARP-1 gene expression in all types of primary human cancer and compared the results to normal counterpart tissue. PARP expression was above the 95 percent upper confidence limit for normal tissue in ovarian cancer, intraductal breast cancer, lung cancer and uterine cancer. In contrast, prostate tumor tissue showed minimal PARP overexpression.

BSI-201 has been tested as both monotherapy and in combination with standard therapy in Phase 1 studies in patients with solid tumors. BiPar is preparing to initiate Phase 1b and Phase 2 trials of BSI-201 in several specific tumor types guided largely by gene expression data.

About PARP

PARP-1 plays a central role in cell proliferation and in DNA repair. BiPar's novel, proprietary PARP inhibitors are a new generation of drug candidates that show promising activity and a favorable toxicity profile. Preclinica
'/>"/>

SOURCE BiPar Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Rosetta Genomics to Webcast Presentation at CE Unterberg, Towbin Emerging Growth Opportunities Conference
2. Rosetta Genomics and Weizmann Institute Scientists Identify Role of microRNA in Cancer Suppression
3. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
4. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
5. Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection
6. Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference
7. DNA Therapeutics Reports a Novel Mechanism of Action and a Biomarker of its Lead Molecule Dbait That Open an Innovative Pathway-Targeting in Molecular Cancer Therapy
8. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
9. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
10. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
11. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014 Astellas ... head of corporate and employee communications in the ... Jeff Winton , senior vice president, chief communications ... for developing and leading corporate brand initiatives and ... across North and South America ...
(Date:7/31/2014)... -- Cryoport, Inc. (OTCBB: CYRX) today announced financial results ... Recent Operating Highlights , Achieved ... month period ended June 30, 2014 compared to the ... further expand Cryoport,s global reach using the ,powered by ... Immudex, an immunotherapy and vaccine development services company, to ...
(Date:7/31/2014)... 2014 Nutrastar International Inc. (OTCQB: NUIN; "Nutrastar" ... premium branded consumer products, including commercially cultivated Cordyceps Militaris ... announced the signing of its first distributor for its ... Hubei Province located ... . The contract with the ...
Breaking Medicine Technology:Astellas Hires Industry Veteran Moyra Knight as Head of Corporate and Employee Communications 2Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 2Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 3Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 4Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 5Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 6Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 7Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 8Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 2Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 3Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 4
... Confirm Robust Efficacy of CIMZIA, BOSTON, Nov. ... new,Phase III data from the RAPID 1 and ... Annual Scientific Meeting (ACR), which show,CIMZIA(R) (certolizumab pegol), ... Factor), given with methotrexate, is significantly,more effective than ...
... Fla., Nov. 7 A new analysis,presented today ... Evaluation Of Rosuvastatin) showed CRESTOR(R) (rosuvastatin calcium) 40,mg ... in four,patient populations at varying levels of risk ... subjects defined by the Framingham risk,assessment tool as ...
Cached Medicine Technology:CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 2CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 3CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 4CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 5CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 6CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 7CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 8New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 2New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 3New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 4New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 5New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 6
(Date:7/31/2014)... the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) and ... will expedite the delivery of laboratory samples and ... districts of the Northern and Central Zones of ... for Health will establish a dependable and coordinated ... critical bottleneck in health services for the more ...
(Date:7/31/2014)... View, Calif. and Las Vegas, Nevada (PRWEB) July 31, ... partnership with LaunchKey to provide next generation authentication services ... simple and secure way to utilize hardware protected multi-factor ... enormous problem in the Internet's reliance on password-based authentication. ... hacks and global data breaches taking place around the ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 The ... to reach USD 37.83 billion by 2020, according ... Inc. Increasing geriatric population base augmenting the susceptibility ... orthopedic, and respiratory diseases coupled with increasing patient ... over the next six years. Some of the ...
(Date:7/31/2014)... 31, 2014 (HealthDay News) -- Recovery time after surgery ... known as statins, according to a new study. ... affect the body,s inflammatory response, reducing the amount of ... seemed to be particularly true among people who tend ... of the most widely prescribed medications in the world. ...
(Date:7/31/2014)... 2014 A new catheter being ... helping patients who have an abnormal heart rhythm. ... ablation procedures for patients such as those suffering ... Baptist Heart Specialists were the first in north ... past spring, according to Biosense Webster, which develops ...
Breaking Medicine News(10 mins):Health News:Elizabeth Glaser Pediatric AIDS Foundation partners with Riders for Health in Malawi 2Health News:Rivetz Partners with LaunchKey to Offer Next Generation Authentication for Accounts Leveraging Trusted Execution Technology. 2Health News:Rivetz Partners with LaunchKey to Offer Next Generation Authentication for Accounts Leveraging Trusted Execution Technology. 3Health News:Medical Imaging Systems - Global Industry Trends, Size, Share, Opportunity, Growth, Outlook, Segmentation and Forecast from 2014 to 2020 - Grand View Research, Inc. 2Health News:Medical Imaging Systems - Global Industry Trends, Size, Share, Opportunity, Growth, Outlook, Segmentation and Forecast from 2014 to 2020 - Grand View Research, Inc. 3Health News:Medical Imaging Systems - Global Industry Trends, Size, Share, Opportunity, Growth, Outlook, Segmentation and Forecast from 2014 to 2020 - Grand View Research, Inc. 4Health News:Medical Imaging Systems - Global Industry Trends, Size, Share, Opportunity, Growth, Outlook, Segmentation and Forecast from 2014 to 2020 - Grand View Research, Inc. 5Health News:Medical Imaging Systems - Global Industry Trends, Size, Share, Opportunity, Growth, Outlook, Segmentation and Forecast from 2014 to 2020 - Grand View Research, Inc. 6Health News:Cholesterol Drugs May Speed Healing After Surgery 2Health News:New Catheter Improves Outcomes for Abnormal Heart Beat 2Health News:New Catheter Improves Outcomes for Abnormal Heart Beat 3
... near the World Trade Center had sleeplessness, other problems, ... Direct exposure to the World Trade Center terrorist ... , The study, by researchers at the Mount Sinai ... children averaging about 4 years of age who lived ...
... Merrill Lynch,s Global Pharmaceutical Conference Feb. ... 5, 2008, ... it will host a conference call and live webcast on,Wednesday, Feb. 27, 2008, ... ended Dec. 31, 2007. The Company also will provide,an operational and integration update ...
... CLARA, Calif., Feb. 5 Coherent, Inc.,(Pink Sheets: COHR), ... included in the company,s proxy for the annual meeting ... subject to election by,shareholders. The nominees include current directors ... Vij as well as first-time,nominees Susan James and Clifford ...
... Engineering,Group Inc. (NYSE: JEC ) announced today that ... in managing the Sequoia Hospital Program,in Redwood City, Calif. ... including a new 104-bed tower, a retrofit of 63 ... a parking structure. The,overall project is expected to be ...
... VIEW, Calif., Feb. 5 MAP,Pharmaceuticals, Inc. (Nasdaq: ... B. Shrewsbury, M.B., Ch.B., Chief Medical,Officer, will be leaving ... Shrewsbury plans to provide consulting services to the company,for ... want to thank Steve for his many contributions and ...
... Feb. 5 Favrille, Inc. (Nasdaq:,FVRL), a biopharmaceutical ... cancer, announced today that it will,host a conference ... Time on,Tuesday, February 19, 2008 to discuss the ... A press release will be issued before the ...
Cached Medicine News:Health News:9/11 Exposure Linked to Behavior Trouble in Kids 2Health News:Mylan Schedules Financial Results Conference Call and Live Webcast for the Quarter and Nine Months Ended Dec. 31, 2007 2Health News:Coherent Announces Director Slate for Upcoming Annual Meeting 2Health News:Jacobs Receives Contract from Catholic Healthcare West to Assist Sequoia Hospital Expansion Program 2Health News:MAP Pharmaceuticals Announces Resignation of Chief Medical Officer 2Health News:Favrille to Host Conference Call and Live Webcast to Discuss Fourth Quarter and Year End 2007 Financial Results on February 19, 2008 2
PremierEdge Stab Knives - 30....
... for the total eye. Whether used ... mode or set independently to accommodate ... settings are adjustable to accommodate maximizing ... for use with tonometer-mounted, hand-held and ...
PremierEdge™ MVR Knives. Angled....
VISCO SHIELD Viscoelastic. Complete with 23g x 7/8" Thin Wall Cannula....
Medicine Products: